

TMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US)

217550US0PCT

U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR

10/031371

INTERNATIONAL APPLICATION NO. PCT/EP00/06545

INTERNATIONAL FILING DATE 10 JULY 2000

PRIORITY DATE CLAIMED 19 JULY 1999

TTORNEY'S DOCKET NUMBER

TITLE OF INVENTION

		ISTIC COMPOSITION COMPRISING DAUNORUBICIN DERIVATIVES AND ANTIMETABOLITE UNDS
APPL	ICAN'	T(S) FOR DO/EO/US
Mar	ia C.	GERONI, et al.
Appl	icant l	herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:
1.		This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.
2.		This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.
3.	×	This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include itens (5), (6), (9) and (24) indicated below.
4.	\boxtimes	The US has been elected by the expiration of 19 months from the priority date (Article 31).
5.	\boxtimes	A copy of the International Application as filed (35 U.S.C. 371 (c) (2))
		a. is attached hereto (required only if not communicated by the International Bureau).
		b. 🛮 has been communicated by the International Bureau.
		c. is not required, as the application was filed in the United States Receiving Office (RO/US).
6.		An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).
		a. is attached hereto.
		b. has been previously submitted under 35 U.S.C. 154(d)(4).
7.	\boxtimes	Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3))
		a. are attached hereto (required only if not communicated by the International Bureau).
		b. have been communicated by the International Bureau.
		c. have not been made; however, the time limit for making such amendments has NOT expired.
		d. 🛮 have not been made and will not be made.
8.		An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
9.		An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)).
10.		An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)).
11.	\boxtimes	A copy of the International Preliminary Examination Report (PCT/IPEA/409).
12.	\boxtimes	A copy of the International Search Report (PCT/ISA/210).
It	tems 1	13 to 20 below concern document(s) or information included:
13.	\boxtimes	An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
14.		An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
15.	\boxtimes	A FIRST preliminary amendment.
16.		A SECOND or SUBSEQUENT preliminary amendment.
17.		A substitute specification.
18.		A change of power of attorney and/or address letter.
19.		A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821 - 1.825.
20.		A second copy of the published international application under 35 U.S.C. 154(d)(4).
21.		A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).
22.		Certificate of Mailing by Express Mail
23.	\boxtimes	Other items or information:
		Notice of Priority / PCT/IB/304 / PCT/IB/308 PTO-1449

U.S. AI	PPLICATIO	N NO. (IF KNO	31371	INTERNATIONAL A PCT/E	APPLICAT P00/065 4		10.		217550	DOCKET NU USOPCT	MBER
24.	The	following fees a	are submitted:.					CA	LCULATIONS	PTO USE	ONLY
	Neither in	ternational prel	37 CFR 1.445(a)(2))	fee (37 CFR 1.482) n			\$1040.00	,	,		
×	Internation	nal preliminary ut International	examination fee (37 Search Report prepa	CFR 1.482) not paid ared by the EPO or JPO	to O		\$890.00	,			
. 🗆	Internation	nal preliminary	examination fee (37	CFR 1.482) not paid (2)) paid to USPTO	to USPTO)	\$740.00	,			
	but all cla	ims did not sati	sfy provisions of PC	CFR 1.482) paid to UT Article 33(1)-(4)			\$710.00				
	Internation and all cla	ims satisfied pr	ovisions of PCT Art	CFR 1.482) paid to Uicle 33(1)-(4)			\$100.00	·	· · · · · ·		
		_		ATE BASIC FE				·	\$890.00		
Surcha months	rge of \$13 from the	0.00 for furnish earliest claimed	ing the oath or decla priority date (37 Cl	FR 1.492 (e)).		0	⊠ 30		\$130.00		
CLA	AIMS	NUN	MBER FILED	NUMBER EXT	`RA		RATE	<u> </u>			
Total c			13 - 20 =	0		х	\$18.00		\$0.00		
	ndent clair		1 - 3=	0		х	\$84.00	+	\$0.00 \$0.00		
Multip	le Depende	ent Claims (che	ck if applicable).	ABOVE CALO	TLAT	TOP		+	\$1,020.00		
□ A	pplicant cl	aims small enti	·····	R 1.27). The fees indic					\$0.00		
					SUB	roī	$\Gamma AL =$		\$1,020.00		
Process months	sing fee of from the	\$130.00 for fur earliest claimed	nishing the English priority date (37 CI	translation later than FR 1.492 (f)).	□ 20	0	□ 30 +		\$0.00		
				TOTAL NAT	IONA	L FF	EE =		\$1,020.00		
Fee for accomp	recording panied by a	the enclosed as an appropriate c	signment (37 CFR 1 over sheet (37 CFR	.21(h)). The assignment of the state of the	ent must l applicabl	oe le).			\$0.00		
				TOTAL FEES	ENCL	OSI	ED =		\$1,020.00		
								Am	ount to be: refunded	\$	
									charged	\$	
a.	_	check in the an	nount of \$1,020 Deposit Account No		above fee				to cover th	e above fees	
b.	A	duplicate copy	of this sheet is enclo	sed.							
c.	to	Deposit Accou	nt No. <u>15-0030</u>	 · ·	y of this	sheet	is enclosed	i.			
d.				. WARNING: Inform on this form. Provide							
				CFR 1.494 or 1.495 te the application to p				ition to	revive (37 CFI	?	
SEND	ALL COR	RESPONDENC	CE TO:					/			
						SIC	AM GNATURE	wdi	, surar		
		1000000				No	rman F.	Oblor	1		
						NA	ME		•		
		2	2850			24,	618		,		
		_	_			RE	GISTRAT	ION N	UMBER		
(703)	413-3000			r Sachar No. 34,423				àn	18 2002		
						DA	.IE				

Docket No.

217550US0PCT

IN RE APPLICATION OF: Maria C. GERONI, et al.

SERIAL NO:

NEW U.S. PCT APPLICATION BASED ON PCT/EP00/06545

FILED:

HEREWITH

SYNERGISTIC COMPOSITION COMPRISING DAUNORUBICIN DERIVATIVES AND

FOR:

ANTIMETABOLITE COMPOUNDS

ASSISTANT COMMISSIONER FOR PATENTS WASHINGTON, D.C. 20231

SIR:

Transmitted herewith is an amendment in the above-identified application.

No additional fee is required

Small entity status of this application under 37 C.F.R. §1.9 and §1.27 is claimed.

Additional documents filed herewith:

Preliminary Amendment/Notice of Priority/PCT/IB/304/PCT Transmittal Letter PCT/IB/308/International Search Report/Information Disclosure Statement International Preliminary Examination Report/PTO-1449/Check for \$1,020.00

The Fee has been calculated as shown below:

CLAIMS	CLAIMS REMAINING		HIGHEST NUMBER PREVIOUSLY PAID	NO. EXTRA CLAIMS		RATE		CALCULATIONS
TOTAL	13	MINUS	20	0	×	\$18	=	\$0.00
INDEPENDENT	1	MINUS	3	0	×	\$84	=	\$0.00
		☐ MULTIPLE DEPENDENT CLAIMS				\$280	=	\$0.00
		TOTAL OF ABOVE CALCULATIONS						\$0.00
		☐ Reduction by 50% for filing by Small Entity						\$0.00
		☐ Recordation of Assignment				\$40	=	\$0.00
						TOTA	٩L	\$0.00

☐ A check in the amount of \$0.00 is attached.

- ☑ Please charge any additional Fees for the papers being filed herewith and for which no check is enclosed herewith, or credit any overpayment to deposit Account No. 15-0030. A duplicate copy of this sheet is enclosed.
- 🖾 If these papers are not considered timely filed by the Patent and Trademark Office, then a petition is hereby made under 37 C.F.R. §1.136, and any additional fees required under 37 C.F.R. §1.136 for any necessary extension of time may be charged to Deposit Account No. 15-0030. A duplicate copy of this sheet is enclosed.

OBLON, SPIVAK, McCLELLAND, MAIER & NEUSTADT, P.C.

Norman F. Oblon

Registration No. 24,618

Surinder Sachar

Registration No. 34,423

Customer Number 22850 Tel. (703) 413-3000 Fax. (703) 413-2220 (OSMMN 10/01)

JC13 Pec'd PCT/PTO 18 JAN 2002



DOCKET NO.: 217550 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Maria C. GERONI, et al.

SERIAL NO.: NEW U.S. PCT APPLICATION

FILED: HEREWITH

INTERNATIONAL APPLICATION NO.: PCT/EP00/06545

INTERNATIONAL FILING DATE: July 10, 2000

FOR: SYNERGISTIC COMPOSITION COMPRISING DAUNORUBICIN DERIVATIVES AND

ANTIMETABOLITE COMPOUNDS

REQUEST FOR PRIORITY UNDER 35 U.S.C. 119 AND THE INTERNATIONAL CONVENTION

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

In the matter of the above-identified application for patent, notice is hereby given that the applicant claims as priority:

COUNTRY

APPLICATION NO

DAY/MONTH/YEAR

Great Britain

9916882.5

19 July 1999

Certified copies of the corresponding Convention application(s) were submitted to the International Bureau in PCT Application No. PCT/EP00/06545. Receipt of the certified copy(s) by the International Bureau in a timely manner under PCT Rule 17.1(a) has been acknowledged as evidenced by the attached PCT/IB/304.

Respectfully submitted, OBLON, SPIVAK, McCLELLAND, MAIER & NEUSTADT, P.C.

Norman F. Oblon

Attorney of Record

Registration No. 24,618

Surinder Sachar

Registration No. 34,423

22850

22850

(703) 413-3000 Fax No. (703) 413-2220 (OSMMN 1/97)